Spotlight on paroxetine in psychiatric disorders in adults

CNS Drugs

Volumn 16, Issue 6, 2002, Pages 425-434

  Wagstaff, Antona J ^a   Cheer, Susan M ^a   Matheson, Anna J ^a   Ormrod, Douglas ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; TIANEPTINE; TRAZODONE; VENLAFAXINE;

ANOREXIA; ANXIETY NEUROSIS; ASTHENIA; COMORBIDITY; CONSTIPATION; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; HEADACHE; HUMAN; NAUSEA; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SOMNOLENCE; TREMOR; VERTIGO;

EID: 0036278928     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216060-00006     Document Type: Review

References (103)

1. Paroxetine: An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders
2. Human monoamine transporter binding profile of the SSRIs
3. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers
4. Paroxetine: A review of its use in social anxiety disorder
5. The effects of paroxetine and nefazodone on sleep: A placebo controlled trial
6. A review of the psychomotor effects of paroxetine
7. Cardiovascular effects of antidepressants: Studies of paroxetine in healthy men and depressed patients
8. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment
9. Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings
10. A review of the metabolism and pharmacokinetics of paroxetine in man
11. The pharmacokinetics of paroxetine in the elderly
12. The pharmacokinetics of paroxetine in renal impairment
13. The pharmacokinetics of paroxetine in patients with liver cirrhosis
14. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety depression
15. Overview of the pharmacokinetics of fluvoxamine
16. A comparison of paroxetine and placebo in depressed outpatients
17. A placebo- and imiprarrane-controlled study of paroxetine
18. Paroxetine in major depression: A double-blind trial with imipramine and placebo
19. A comparison of paroxetine, imipramine and placebo in depressed outpatients
20. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients
21. A study comparing paroxetine placebo and imipramine in depressed patients
22. A double-blind comparison of paroxetine, imipramine, and placebo in major depression
23. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients
24. Paroxetine and amitriptyline in the treatment of depression in general practice
25. A double-blind multicentre comparison of paroxetine and amitriptyline in Australian general practice
26. Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes: Double- blind, parallel group study with amitriptyline HCl
27. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients
28. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients
29. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice
30. Treatment of major depression in general practice: A double-blind comparison of paroxetine and lofepramine
31. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
32. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients
33. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression
34. Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in anxious depression
35. A double blind comparison of paroxetine and fluoxetine in patients with major depression
36. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression
37. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression
38. Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy
39. Controlled comparison of paroxetine and fluvoxamine in major depression
40. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients
41. A double-blind study comparing paroxetine and maprotiline in depressed outpatients
42. Paroxetine in the treatment of depression: A double-blind multicenter study versus mianserin
43. Effects of mirtazapine, paroxetine and their combination: A double-blind study in major depression
44. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression
45. Efficacy and safety of tianeptine in major depression: Evidence from a 3- month controlled clinical trial versus paroxetine
46. Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episodes: Double-blind, parallel group study with trazodone HCl
47. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice
48. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
49. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression
50. A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients
51. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients
52. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-Week outcome
53. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression
54. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients
55. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression
56. Paroxetine for the prevention of depression induced by high-dose interferon alfa
57. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial
58. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency
59. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: A double-blind study
60. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
61. Treatment of depression in patients with breast cancer: A comparison between paroxetine and amitriptyline
62. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: A randomized, double blind, parallel group study
63. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients
64. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease
65. A randomised, double-blind, controlled study of paroxetine and fluoxetine in the treatment of patients with major depression associated with anxiety
66. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety
67. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: An international, 6-week double-blind study
68. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults
69. Treatment of dysthymia and minor depression in primary care: A randomized trial in patients aged 18 to 59 years
70. A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder
71. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
72. Long-term treatment and prevention of relapse of OCD with paroxetine
73. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine
74. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study
75. Paroxetine in the treatment of panic disorder, a randomised, double-blind, placebo-controlled study
76. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
77. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder
78. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
79. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder
80. A comparison of citalopram and paroxetine in the treatment of panic disorder: A randomized, single-blind study
81. Paroxetine in social anxiety disorder: A randomized placebo-controlled study
82. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study
83. Therapeutic advances: Paroxetine for the treatment of social anxiety disorder
84. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
85. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa
86. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder
87. Maintained efficacy of paroxetine in the treatment of social anxiety disorder
88. Short-term efficacy of paroxetine in social anxiety disorder is maintained after long-term treatment
89. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial
90. Paroxetine efficacy in the treatment of generalized anxiety disorder
91. Efficacy and tolerability of paroxetine for long-term treatment of GAD
92. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study
93. Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial
94. Paroxetine efficacy in male and female patients with PTSD
95. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction: Incidence, possible aetiology and implications for management
96. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients
97. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression